Poll: 67% Want In-Person Visits Before Abortion Pills Are Mailed
New polling shows broad bipartisan support for requiring an in-person doctor visit before abortion pills are shipped, as pro-life groups press the Trump FDA to restore stricter safeguards.
A new poll is saying the quiet part out loud: Americans are not exactly thrilled with the idea of abortion pills being dropped in the mail like a birthday card from Aunt Linda.
According to polling obtained by The Daily Wire, 67 percent of Americans support reinstating an in-person doctor visit requirement before abortion pills are mailed. That includes 72 percent of Republicans, 68 percent of independents, and even 63 percent of Democrats. In a political era where people cannot agree on lunch, that kind of number gets your attention.
The survey, conducted by CRC Research for the 85 Fund, lands right in the middle of a growing push from pro-life physicians and advocates urging the Trump administration's FDA to revisit the Biden-era loosening of abortion pill rules. And honestly, it is not hard to see why. When a drug with known risks can be prescribed under a system that allows mailing and remote distribution, people are going to ask whether safety got bumped down the priority list so activists could call it progress.
The polling tells a pretty clear story
The top-line number is strong enough on its own, but the details are where the case really sharpens.
67 percent support bringing back an in-person doctor visit before abortion pills are mailed.
70 percent support requiring an in-person medical evaluation before and after taking the abortion pill.
62 percent said they were more likely to support an in-person requirement after learning about cases of coercion.
49 percent said they would be less likely to support a representative who backs shipping abortion pills without a medical evaluation.
That is not some narrow church-basement sample. According to The Daily Wire's report, CRC Research surveyed 1,600 likely voters from March 12 through March 18.
Who saw that coming? Well, pretty much anyone who understands that normal people still think medical decisions involving a dangerous drug and an unborn child should involve an actual doctor visit.
What the FDA rule currently allows
The FDA's own mifepristone information page makes the issue plain. Under the current Mifepristone REMS Program, the drug must be prescribed by a certified prescriber and dispensed either under the supervision of a certified prescriber or by a certified pharmacy on a prescription from one. The key change is this: it may be dispensed in person or by mail.
That change did not happen in a vacuum. The FDA states that after a 2021 review, it modified the REMS program, and in January 2023 approved a further change allowing certified pharmacies to dispense the drug, including shipping with tracking information. The agency says those changes were intended to reduce burdens on the health care system while keeping the benefits of the product greater than its risks.
But even the FDA also warns that it does not recommend buying mifepristone outside the REMS system because doing so bypasses safeguards designed to protect patient health. Which is kind of the whole point, isn't it? If safeguards matter, then weakening direct medical oversight was always going to trigger skepticism.
Why pro-life groups are pressing now
Pro-life physicians have argued for years that the shift toward mail-order abortion pills increases the likelihood of missed ectopic pregnancies, coercion, complications, and pressure on women who may already be vulnerable.
"It's overwhelmingly clear that Americans support reinstating the in-person dispensing requirement to protect women taking mifepristone," American Association of Pro-Life OBGYNs CEO Dr. Christina Francis told The Daily Wire.
And then there is the federalism problem. Pro-life leaders argue that when pills can be shipped across state lines, state abortion protections become easier to sidestep. A state can pass a law. Activists can answer with padded envelopes and legal gymnastics. Because of course they can.
The poll suggests voters are catching on. Americans may disagree on abortion broadly, but many still understand a basic principle: if a serious drug is involved, medical oversight should be more than a checkbox on a screen.
The bipartisan number matters
The Democratic support figure may be the most revealing part of this whole story. Sixty-three percent of Democrats backing an in-person requirement tells you this is not just a base-mobilization message for the right. It tells you the public is more cautious than the activists who dominate elite institutions.
That gap matters. The media often frames any abortion-pill safeguard as an attack on women. The poll says a lot of women and men, including many Democrats, are not buying that script. They see a common-sense safeguard as exactly that: common sense.
What the Trump FDA should do
President Trump has broad support from pro-life voters, and this is one of those areas where action would line up with both principle and public opinion. Reinstating the in-person doctor visit requirement would not ban the drug outright. It would simply restore a measure of direct medical accountability before a life-ending drug gets mailed across the country.
That is not radical. It is what most Americans in this poll already support.
The bigger lesson here is simple. When the activist class says safety rules are oppressive, check the numbers. Regular Americans still believe medicine should involve doctors, not just shipping labels. And when even Democrats are saying, "Maybe someone should actually see the patient first," the bureaucracy should probably take the hint.